Insights On Drug Development

31. Developing A Control Strategy And Minimizing Risk In Phase 1 Injectable Drug Development 9/11/2025

    See how investing early in the right controls not only minimizes risks but also accelerates timelines, streamlines regulatory interactions, and builds trust across the ecosystem.

32. Early-Stage Drug Development: Navigating The Trends That Shape Tomorrow's Therapies 9/11/2025

    From AI to adaptive trial designs, the industry is undergoing a transformation that is equal parts scientific breakthrough and strategic recalibration. Learn what innovations are poised to redefine pipelines.

33. Nanoforming Biologics, GLP-1s: From I.V. To Sub Q And Inhaled Delivery 9/9/2025

    Developing new delivery routes is essential for creating more effective treatments. Nanoforming enables new routes to simplify dosing, enhance patient comfort, and reduce healthcare costs.

34. Development Of A Non-Standard Protein Therapeutic 9/9/2025

    Discover how a tailored development approach transformed a complex therapeutic protein into a candidate ready for early-stage clinical trials.

35. Phenotypic Characterization Of Bleomycin-Induced Pulmonary Fibrosis Mod 9/8/2025

    To gain deeper biological insight, lung injury in this model has been further characterized through cellular phenotyping, gene expression analysis, and cytokine profiling.

36. Managing Endotoxins - Detect, Prevent, Remove 9/8/2025

    Explore the risks of endotoxin contamination in drug manufacturing and discover sustainable, animal-free detection methods to ensure pharmaceutical safety and regulatory compliance.

37. Strategic Approaches To Controlled Release Formulation: Polymer Screening And Case Study Insights 9/4/2025

    Discover how early polymer selection drives formulation success, with case studies linking polymer choice to drug release and practical insights for developing robust CR products.

38. Liposomal And Nanoparticle Technology 9/3/2025

    Specializing in oncology, anti-infective, and complex formulations, Pfizer Melbourne provides manufacturing services for sterile dosage forms.

39. Accelerating IND-Enabling Studies With Automated Bioanalysis Workflows 9/2/2025

    Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation—helping companies move therapies forward with greater confidence.

40. Why Bioanalysis Needs To Break Free From Manual Bottlenecks 9/2/2025

    Bioanalysis remains one of the most persistent bottlenecks in drug development, with CROs displaying inefficiencies that are no longer operational nuisances but strategic liabilities.